HAVRÁNKOVÁ, Eva, V. GARAJ, S. MASCARETTI, A. ANGELI, Zuzana SOLDÁNOVÁ, M. KEMKA, J. MOTYČKA, Marie BRÁZDOVÁ, Jozef CSÖLLEI, J. JAMPÍLEK a C.T. SUPURAN. Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2022, roč. 23, č. 1, s. 1-45. ISSN 1422-0067. Dostupné z: https://dx.doi.org/10.3390/ijms23010231.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors
Autoři HAVRÁNKOVÁ, Eva (203 Česká republika, garant, domácí), V. GARAJ, S. MASCARETTI, A. ANGELI, Zuzana SOLDÁNOVÁ (203 Česká republika, domácí), M. KEMKA, J. MOTYČKA, Marie BRÁZDOVÁ (203 Česká republika, domácí), Jozef CSÖLLEI (203 Česká republika, domácí), J. JAMPÍLEK a C.T. SUPURAN.
Vydání International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2022, 1422-0067.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.600
Kód RIV RIV/00216224:14160/22:00125425
Organizační jednotka Farmaceutická fakulta
Doi http://dx.doi.org/10.3390/ijms23010231
UT WoS 000751345900001
Klíčová slova anglicky vancomycin-resistant enterococci; carbonic anhydrase; inhibition; triazine; benzenesulfonamide; stilbene; chalcone
Štítky rivok, ÚChL, ÚMF
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: JUDr. Sabina Krejčiříková, učo 383857. Změněno: 23. 2. 2022 14:08.
Anotace
A series of 1,3,5-triazinyl aminobenzenesulfonamides substituted by aminoalcohol, aminostilbene, and aminochalcone structural motifs was synthesized as potential human carbonic anhydrase (hCA) inhibitors. The compounds were evaluated on their inhibition of tumor-associated hCA IX and hCA XII, hCA VII isoenzyme present in the brain, and physiologically important hCA I and hCA II. While the test compounds had only a negligible effect on physiologically important isoenzymes, many of the studied compounds significantly affected the hCA IX isoenzyme. Several compounds showed activity against hCA XII; (E)-4-{2-[(4-[(2,3-dihydroxypropyl)amino]-6-[(4-styrylphenyl)amino]-1,3,5-triazin-2-yl)amino]ethyl}benzenesulfonamide (31) and (E)-4-{2-[(4-[(4-hydroxyphenyl)amino]-6-[(4-styrylphenyl)amino]-1,3,5-triazin-2-yl)amino]ethyl}benzenesulfonamide (32) were the most effective inhibitors with K(I)s = 4.4 and 5.9 nM, respectively. In addition, the compounds were tested against vancomycin-resistant Enterococcus faecalis (VRE) isolates. (E)-4-[2-({4-[(4-cinnamoylphenyl)amino]-6-[(4-hydroxyphenyl)amino]-1,3,5-triazin-2-yl}amino)ethyl]benzenesulfonamide (21) (MIC = 26.33 mu M) and derivative 32 (MIC range 13.80-55.20 mu M) demonstrated the highest activity against all tested strains. The most active compounds were evaluated for their cytotoxicity against the Human Colorectal Tumor Cell Line (HCT116 p53 +/+). Only 4,4'-[(6-chloro-1,3,5-triazin-2,4-diyl)bis(iminomethylene)]dibenzenesulfonamide (7) and compound 32 demonstrated an IC50 of ca. 6.5 mu M; otherwise, the other selected derivatives did not show toxicity at concentrations up to 50 mu M. The molecular modeling and docking of active compounds into various hCA isoenzymes, including bacterial carbonic anhydrase, specifically alpha-CA present in VRE, was performed to try to outline a possible mechanism of selective anti-VRE activity.
Návaznosti
MUNI/A/1202/2020, interní kód MUNázev: Syntéza nových potenciálních inhibitorů CA
Investor: Masarykova univerzita, Syntéza nových potenciálních inhibitorů CA
VytisknoutZobrazeno: 17. 7. 2024 07:22